SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001072613-22-000489
Filing Date
2022-07-19
Accepted
2022-07-19 17:28:49
Documents
1
Group Members
ALI BEHBAHANIANTHONY A. FLORENCE, JR.CARMEN CHANGEDWARD T. MATHERSLIZA LANDSMANMOHAMAD H. MAKHZOUMINEA 18 VENTURE GROWTH EQUITY, L.P.NEA 18 VGE GP, LLCNEA PARTNERS 18 VGE, L.P.PAUL WALKERPETER W. SONSINIRICK YANGSCOTT D. SANDELL

Document Format Files

Seq Description Document Type Size
1 GROWTH EQUITY OPPORTUNITIES 18 VGE, LLC / X4 PHARMACEUTICALS, INC. -- SCHEDULE 1 growthequity-x4pharma_18631.htm SC 13D 508015
  Complete submission text file 0001072613-22-000489.txt   510110
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Subject) CIK: 0001501697 (see all company filings)

IRS No.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-90199 | Film No.: 221092304
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093
Business Address 1954 GREENSPRING DRIVE SUITE 600 TIMONIUM MD 21093 410-842-4000
Growth Equity Opportunities 18 VGE, LLC (Filed by) CIK: 0001917895 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D